Good afternoon :)
$
₹
CytoMed Therapeutics Limited Ordinary Shares

CytoMed Therapeutics Limited Ordinary Shares

GDTC

NASDAQ
Asset Logo

CytoMed Therapeutics Limited Ordinary Shares

GDTC

NASDAQ
$0.807.12% (-0.06)
$
₹
$0.807.12% (-0.06)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $10.3M the stock is ranked 5724

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.98
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.27
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 1 analyst's reports

Buy
1 analyst
Hold
0 analyst
Sell
0 analyst

Analysts expect a +474.71% price upside over the next year

Current Price$0.80
Target Price$5

Company Profile

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
70.27
70.27
1Y Return
19.08%
19.08%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
24.43
24.43
1Y Return
41.43%
41.43%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
27.55%
27.55%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
30.83
30.83
1Y Return
31.43%
31.43%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
20.06
20.06
1Y Return
45.3%
45.3%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
CytoMed Therapeutics Limited Ordinary Shares -1.98-
AbbVie Inc70.2750.450.36
Amgen Inc24.4320.222.10

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

0.1
-1.1
0.1
-1.1
0.2
-0.8
0.1
-1.7
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Revenue
Net Income
Financial YearQ3 2023Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Total Revenue0.11-0.110.110.14-0.130.130.200.16
Net Income-0.98-1.46-0.54-1.09-0.72--1.12-1.12-0.86-1.73
Net Profit Margin-883.53%--485.50%-977.37%-511.59%--834.68%-834.68%-423.41%-1030.69%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. CytoMed Therapeutics Limited Ordinary Shares (GDTC) share price today is $0.80 as of September 10, 2026 at 1:30 AM IST. The stock touched a day high of $0.87 and a day low of $0.79.

  2. CytoMed Therapeutics Limited Ordinary Shares stock trades on NASDAQ under the ticker symbol GDTC.

  3. CytoMed Therapeutics Limited Ordinary Shares's market capitalization is $10.29M as of September 10, 2026 at 1:30 AM IST.

  4. CytoMed Therapeutics Limited Ordinary Shares's price-to-earnings (P/E) ratio is N/A as of September 10, 2026.

  5. CytoMed Therapeutics Limited Ordinary Shares's price-to-book (P/B) ratio is 1.98 as of September 10, 2026.

  6. Yes, You can buy CytoMed Therapeutics Limited Ordinary Shares shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy CytoMed Therapeutics Limited Ordinary Shares shares in three steps: 1. Search CytoMed Therapeutics Limited Ordinary Shares on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since CytoMed Therapeutics Limited Ordinary Shares trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in CytoMed Therapeutics Limited Ordinary Shares (GDTC) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 12.3762 shares at the current price of $0.80.

Loading...